去甲万古霉素与万古霉素抗MRSA作用的药物经济学研究

 目的 研究去甲万古霉素与万古霉素治疗耐甲氧西林金葡球菌(MRSA)感染患者的成本和效果。方法 采用成本-效果分析方法。结果 两组的治疗有效率、不良反应发生率和平均抗生素治疗天数之间无显著性差异(P＞0.05)，而去甲万古霉素组平均总成本小于万古霉素组分别为(3396.4±3631.0)元和(8648.6±3975.2)元，P＜0.05。结论 去甲万古霉素是具有成本-效果的。去甲万古霉素的低药物获得成本是其总成本明显低于万古霉素的主要因素。

Pharmacoeconomics of demethylvancomycin versus vancomycin against MRSA

OBJECTIVE To compare the cost and outcomes of demethylvancomycin and vancomycin for the treatment of MRSA in patients. METHODS A cost-effectiveness analysis was conducted. RESULTS There was no significant difference between the two groups in term of clinical cure rate,adverse-event frequency and the duration of treatment (P＞0.05).The mean total treatment cost per patient in demethylvancomycin-treated group was less than that in vancomycin-treated group 3396.4±3631.0) RMB vs. 8648.6±3975.2) RMB,(P＜0.05). CONCLUSION Demethylvancomycin appeared to be cost-effective in this study.Lower drug acquisition cost of demethylvancomycin was the major reason for its better cost-effectiveness.